Autoimmune pediatric Disorders
Designed specifically for children
Mayo Clinic Laboratories’ first-of-its-kind profile only includes antibodies pertinent to pediatric CNS disorders — all in one evaluation. The antibodies included are supported by clinical research, and test results can help with diagnosis and long-term treatment planning.
Autoimmune pediatric Disorders Test menu
Autoimmune pediatrics
Key testing
- PCDEC | Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Spinal Fluid
- PCDES | Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum
Advantages
- Evaluates for the presence of multiple antibodies with known associations to pediatric-onset central nervous system disorders.
- Requires both serum and spinal fluid samples for improved detection.
- Enables insights on diagnosis, prognosis, and treatment response.
- Facilitates treatment selection.
- GABA-A receptor has a very specific phenotype (88% of patients have refractory seizures).
- Evaluating GABA-A receptor improves diagnostic sensitivity thereby increasing physician confidence.
Highlights
September 29, 2025 - This session provides an in depth overview of evolving diagnostic approaches in neuroimmunology.
Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers relevant to pediatric presentations of the diseases.
The clinical presentations, evaluation (including diagnostic antibody testing), and treatment of autoimmune pediatric CNS disorders, including encephalitides and myelopathies.